title: Concepts about current conditions for the preparation and storage of platelets.
abstract: Substantial experimentation over the last 20 years has led to the conditions that are currently used to prepare and store platelets. Although platelet rich plasma is used in most instances to prepare platelet concentrates, there may be some benefit associated with the use of buffy coats as the source component. Extension of the maximum allowable storage time for platelets to 5 days has been possible as a result of defining the conditions which allow for the better retention of platelet properties. Storage temperature, permeability of the storage container, volume of platelet suspension, and the need to agitate platelets have been identified as key parameters that maintain platelet viability and functional properties. Storage in the 20 to 24 degrees C range prevents a reduction in posttransfusion viability that occurs when platelets are maintained at lower temperatures. Adequate influx of oxygen through container walls to support platelet metabolism and, to a lesser degree, adequate efflux of produced carbon dioxide are essential for maintaining pH levels, a key parameter that also influences posttransfusion viability. Permeability is influenced by container size and material, by use of a satisfactory volume of plasma and by agitating the container. Although platelet concentrates prepared from whole blood have been primarily used to delineate appropriate storage conditions, they also apply to platelets harvested by aphersis technology. Storage under currently used conditions, although providing products with acceptable clinical efficacy, is associated with a reduction in viability and functional characteristics. The development of storage media, specific for platelets, may minimize the occurrence of deleterious changes.
authors.affiliation: American Red Cross, Biomedical Research and Development Laboratories, Rockville, MD 20855.
authors.forename: G
authors.initials: G
authors.lastname: Moroff
authors.forename: S
authors.initials: S
authors.lastname: Holme
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology; D001771:Blood Banks / Q000592:standards; D016913:Blood Component Transfusion; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects; D001793:Blood Preservation / Q000379:methods* / Q000592:standards; D001800:Blood Specimen Collection; D002470:Cell Survival; D015925:Cryopreservation; D003451:Cryoprotective Agents / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D017713:Platelet Transfusion; D010983:Plateletpheresis; D012996:Solutions; D013696:Temperature
chemical_list: D000925:Anticoagulants; D003451:Cryoprotective Agents; D012996:Solutions